Company Overview
Damora Therapeutics, Inc. operates as a clinical-stage biotechnology entity focused on the development of molecule therapeutics designed to treat conditions including fibrosis, cancer, inflammation, and other related diseases. The company is currently advancing specific preclinical small molecule candidates, such as GB3226, which functions as a dual inhibitor of ENL-YEATS and FLT3, alongside GB1211, an oral small molecule agent. This business falls squarely within the broader Healthcare sector and the specific Biotechnology industry, positioning the firm to capitalize on advancements in drug discovery and therapeutic innovation. The company's scale is defined by a substantial market capitalization of $1.59B, while its annual revenue is listed as N/A, and it employs a workforce of 5 individuals. The significant disparity between the $1.59B market cap and the lack of reported revenue, combined with a minimal headcount, indicates that the company's valuation is driven primarily by the potential of its preclinical pipeline rather than current commercial operations. This capitalization suggests a high-risk, high-reward profile typical of early-stage biotech firms where market value is contingent on the successful transition of assets from preclinical research to clinical trials.
Financial Health
The financial performance metrics for Damora Therapeutics, Inc. reveal a company in a burn phase, reporting Net Income (TTM) of $-15,844,000 and EBITDA of $-11,862,000 against N/A revenue. The substantial gap between the N/A revenue and the significant net loss of $-15,844,000 highlights a cost structure dominated by research and development expenses and operational overhead rather than sales costs. The company's Free Cash Flow stands at $-7,066,875, which indicates a continued requirement for external capital injection to sustain operations and fund the advancement of its therapeutic pipeline. Regarding profitability metrics, the company reports a Gross Margin of 0.0%, an Operating Margin of 0.0%, and a Profit Margin of 0.0%, reflecting that no revenue has been generated to date to offset these heavy operational costs. On the balance sheet side, Damora holds $7.61M in cash and short-term investments while carrying a minimal Debt load of $72,000. The Debt to Equity ratio is 0.90, and when comparing the $7.61M cash position against the $72,000 debt, the balance sheet appears conservative in terms of leverage, though the cash reserve is significantly higher than the debt obligation. Liquidity is further supported by a Current Ratio of 3.73, which suggests a strong ability to meet short-term obligations with current assets. Finally, the Return on Equity is -109.5% and the Return on Assets is -43.5%, metrics that reveal management is currently utilizing shareholder capital to generate losses rather than returns, a standard characteristic of clinical-stage development but one that signals negative historical performance on equity deployment.
Valuation Assessment
Valuation multiples for Damora Therapeutics, Inc. are presented as Trailing P/E (TTM) N/A and Forward P/E N/A, reflecting the fact that the company has not yet achieved profitability to generate these standard metrics. The Price to Book ratio is 5.25, which indicates that the market values the company at more than five times its book value, suggesting a premium pricing relative to the tangible assets currently recorded on the balance sheet. Alternative valuation metrics such as Price to Sales (N/A) and EV/EBITDA (-2.43) are utilized, where the negative EV/EBITDA of -2.43 underscores the company's unprofitable status and reliance on future value creation rather than current earnings or sales generation. The stock has exhibited significant volatility over the past year, with a 52-Week High of $38.33 and a 52-Week Low of $2.01. Without a specific current price provided in the available facts, the range itself demonstrates extreme price discovery, having moved from a low of $2.01 to a high of $38.33, illustrating the speculative nature of the investment. The Beta is 1.57, which means the stock's price volatility is expected to be 57% higher than the broader market, indicating high sensitivity to market movements and sector-specific news.
Growth & Income
Growth metrics for Damora Therapeutics, Inc. show Revenue Growth (YoY) as N/A and Earnings Growth (YoY) as N/A, as the company has not yet reported positive revenue to calculate year-over-year expansion rates. The absence of a dividend yield (N/A) and a Payout Ratio of 0.0% confirms that the company does not distribute earnings to shareholders. Because the company is currently unprofitable with negative net income, it does not pay dividends and instead reinvests all available capital, such as the $7.61M in cash, back into research and development to advance its pipeline of molecule therapeutics for fibrosis and cancer. The overall growth and income profile is characterized by a total reliance on capital appreciation potential rather than dividend income or established revenue growth, as the firm remains in the clinical-stage development phase.